| Destiny Nemeth Murphy, DO | |
|
166 South St, Stroke And Brain Injury Rehabilitation, Inc., Shrewsbury, MA 01545-5402 | |
| (508) 842-3935 | |
| (508) 842-3927 |
| Full Name | Destiny Nemeth Murphy |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 17 Years |
| Location | 166 South St, Shrewsbury, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366609315 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 239021 (Massachusetts) | Primary |
| Entity Name | Destiny N Murphy Neurology Consulting Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366809881 PECOS PAC ID: 7719284868 Enrollment ID: O20160405000545 |
News Archive
Researchers at the University of California, San Diego School of Medicine have identified "secondary over-triage" as a potential area of cost savings for our nation's health care. The phenomenon of over-triage occurs when patients are transferred twice, and discharged from a second facility in less than 24 hours. These findings will be published in the September 10th issue of The Journal of Trauma.
PolarCool AB (publ), a Swedish medical device company focusing on treatment of sports-related traumatic brain injury (TBI) and whiplash, today announced that it has submitted a 510(k) pre-market notification to the U.S. Food and Drug Administration (FDA) for the PolarCap System.
According to researchers most couples over 30 will rely more on artificial methods to conceive. This prediction comes from John Yovich, Medical Director of Pivet Medical Centre, and a scientist acknowledged for his pioneering work in IVF, who calls human natural reproduction "a fairly inefficient process."
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
Biotech company Pharming Group NV ("Pharming" or the "Company") has received commitment from bondholders, representing 70% of the nominal amount of the currently outstanding bonds, to accept the offer to convert the bonds as announced on September 21, 2009. Together, they exceed the threshold level of 60% which Pharming set as a minimum participation in order to execute the transaction.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Destiny Nemeth Murphy, DO 130 Gaston St, Medford, MA 02155-1222 Ph: (419) 565-7871 | Destiny Nemeth Murphy, DO 166 South St, Stroke And Brain Injury Rehabilitation, Inc., Shrewsbury, MA 01545-5402 Ph: (508) 842-3935 |
News Archive
Researchers at the University of California, San Diego School of Medicine have identified "secondary over-triage" as a potential area of cost savings for our nation's health care. The phenomenon of over-triage occurs when patients are transferred twice, and discharged from a second facility in less than 24 hours. These findings will be published in the September 10th issue of The Journal of Trauma.
PolarCool AB (publ), a Swedish medical device company focusing on treatment of sports-related traumatic brain injury (TBI) and whiplash, today announced that it has submitted a 510(k) pre-market notification to the U.S. Food and Drug Administration (FDA) for the PolarCap System.
According to researchers most couples over 30 will rely more on artificial methods to conceive. This prediction comes from John Yovich, Medical Director of Pivet Medical Centre, and a scientist acknowledged for his pioneering work in IVF, who calls human natural reproduction "a fairly inefficient process."
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
Biotech company Pharming Group NV ("Pharming" or the "Company") has received commitment from bondholders, representing 70% of the nominal amount of the currently outstanding bonds, to accept the offer to convert the bonds as announced on September 21, 2009. Together, they exceed the threshold level of 60% which Pharming set as a minimum participation in order to execute the transaction.
› Verified 9 days ago
Neelam Varshney, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 14 Shrewsbury Green Dr Unit K, Shrewsbury, Shrewsbury, MA 01545 Phone: 516-984-2430 |